Total Payments
$1,064
2024 Payments
$413.55
Companies
8
Transactions
58
Medicare Patients
2,897
Medicare Billing
$397,719
Payment Breakdown by Category
Food & Beverage$1,052 (98.8%)
Education$12.70 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,052 | 57 | 98.8% |
| Education | $12.70 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $255.40 | 16 | $0 (2024) |
| ViiV Healthcare Company | $206.38 | 10 | $0 (2024) |
| ABBVIE INC. | $186.18 | 8 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $165.83 | 9 | $0 (2024) |
| Allergan, Inc. | $115.65 | 7 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $86.59 | 5 | $0 (2024) |
| PFIZER INC. | $30.71 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $17.62 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $413.55 | 20 | ABBVIE INC. ($120.38) |
| 2023 | $194.73 | 10 | ABBVIE INC. ($49.03) |
| 2022 | $158.34 | 9 | Paratek Pharmaceuticals, Inc. ($74.10) |
| 2021 | $70.53 | 4 | ViiV Healthcare Company ($41.04) |
| 2020 | $18.27 | 1 | Allergan, Inc. ($18.27) |
| 2019 | $85.77 | 6 | Merck Sharp & Dohme Corporation ($72.75) |
| 2018 | $47.75 | 3 | Allergan Inc. ($33.62) |
| 2017 | $75.42 | 5 | Allergan Inc. ($50.74) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/07/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/09/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: HIV | ||||||
| 04/11/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: ANTIBIOTIC | ||||||
| 03/29/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/11/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: ANTIBIOTIC | ||||||
| 12/21/2022 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $12.00 | General |
| 11/15/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: ANTIBIOTIC | ||||||
| 11/14/2022 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/18/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: ANTIBIOTIC | ||||||
| 09/11/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: ANTIBIOTIC | ||||||
| 08/23/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: ANTIBIOTIC | ||||||
| 08/16/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: HIV | ||||||
| 07/22/2022 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: VACCINES | ||||||
| 01/26/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: HIV | ||||||
| 11/01/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/01/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: HIV | ||||||
| 05/26/2021 | Merck Sharp & Dohme Corporation | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/01/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: HIV | ||||||
| 11/25/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/15/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/28/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/03/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DIFICID | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/27/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/13/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/23/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 662 | 1,041 | $260,037 | $85,092 |
| 2022 | 8 | 597 | 1,069 | $253,930 | $90,550 |
| 2021 | 9 | 852 | 1,404 | $300,531 | $120,419 |
| 2020 | 8 | 786 | 1,270 | $262,260 | $101,657 |
Total Patients
2,897
Total Services
4,784
Medicare Billing
$397,719
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 147 | 352 | $60,992 | $21,794 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 120 | 195 | $53,588 | $17,811 | 33.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 91 | 99 | $47,931 | $13,230 | 27.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 120 | 128 | $42,320 | $12,879 | 30.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 102 | $25,506 | $9,293 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 90 | $17,100 | $6,187 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $11,789 | $3,511 | 29.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 23 | 46 | $811.00 | $386.40 | 47.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 140 | 311 | $75,780 | $29,518 | 39.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 140 | 349 | $55,910 | $19,396 | 34.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 113 | 121 | $54,033 | $18,615 | 34.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 56 | 116 | $26,628 | $8,942 | 33.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 56 | 61 | $18,149 | $6,353 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $16,266 | $5,165 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 42 | $6,705 | $2,480 | 37.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 17 | 27 | $459.00 | $80.16 | 17.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 180 | 352 | $79,200 | $33,795 | 42.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 181 | 423 | $63,450 | $25,945 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 122 | 210 | $45,570 | $18,133 | 39.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 103 | 106 | $44,838 | $17,111 | 38.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 138 | 148 | $42,328 | $16,287 | 38.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 37 | 37 | $13,505 | $4,491 | 33.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 50 | 59 | $9,027 | $3,901 | 43.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 16 | 18 | $1,746 | $602.09 | 34.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 25 | 51 | $867.00 | $153.00 | 17.6% |
About Dr. Eric Macapinlac, MD
Dr. Eric Macapinlac, MD is a Internal Medicine healthcare provider based in Sayre, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306819701.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Macapinlac, MD has received a total of $1,064 in payments from pharmaceutical and medical device companies, with $413.55 received in 2024. These payments were reported across 58 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($1,052).
As a Medicare-enrolled provider, Macapinlac has provided services to 2,897 Medicare beneficiaries, totaling 4,784 services with total Medicare billing of $397,719. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Sayre, PA
- Active Since 02/08/2006
- Last Updated 03/24/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306819701
Products in Payments
- AVYCAZ (Drug) $221.55
- DOVATO (Drug) $206.38
- NUZYRA (Drug) $165.83
- PIFELTRO (Drug) $102.80
- ZERBAXA (Drug) $95.63
- REBYOTA (Biological) $74.59
- DALVANCE (Drug) $41.51
- PREVYMIS (Drug) $41.04
- TEFLARO (Drug) $38.77
- PREVNAR 20 (Biological) $30.71
- ISENTRESS (Drug) $15.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Sayre
Jedediah Mcclintic, Md, MD
Internal Medicine — Payments: $9,824
Internal Medicine $9,824
Sahzene Yavuz, Md, MD
Internal Medicine — Payments: $3,956
Internal Medicine $3,956
Subash Ghimire, M.d, M.D
Internal Medicine — Payments: $2,815
Internal Medicine $2,815
Tsujung Yang
Internal Medicine — Payments: $2,502
Internal Medicine $2,502
Rajamurugan Meenakshisundaram, Md, MD
Internal Medicine — Payments: $1,712
Internal Medicine $1,712
Dr. Michael Depersis, D.o, D.O
Internal Medicine — Payments: $1,655
Internal Medicine $1,655